After a sharp drop, Middle Eastern funds and top funds enter the market.

On April 29th, Xingqi Eye Medicine surged by 14.14%. The company's quarterly report showed that in the first quarter of this year, both the Kuwait Investment Authority and the well-known fund manager at Eurasis Investment Management, Mr. Geran, significantly increased their holdings in Xingqi Eye Medicine, both becoming new top ten shareholders. Looking at the stock price trend of Xingqi Eye Medicine, the stock price has experienced significant adjustments since June of last year. According to Xingqi Eye Medicine's first quarter report for 2025, as of the end of the first quarter of this year, the Kuwait Investment Authority has become a new top ten shareholder of Xingqi Eye Medicine, holding 2.9353 million shares; Mr. Geran's Eurasian Medical Health Mixed Fund holds 0.9339 million shares, also becoming a new top ten shareholder.